Breaking News

Synta Appoints Corporate Development VP

By Kristin Brooks | December 20, 2013

Bernitz brings 20 years of corporate strategy experience

Steven Bernitz has been appointed senior vice president of corporate development at Synta Pharmaceuticals. Mr. Bernitz brings more than 20 years of experience in corporate strategy, business leadership and transactional experience in life sciences.
Mr. Bernitz joins the company from Extera Partners, a business development advisory firm, where he served as partner and head of the BioPharma Practice, leading numerous business development and strategy initiatives for development stage companies and their investors, in oncology, autoimmune and orphan diseases.
Prior to Extera, Mr. Bernitz was chief business officer at Concert Pharmaceuticals, and served as senior vice president, business and product development at Coley Pharmaceutical Group. Mr. Bernitz also was chief executive officer of Histogenics and Organogenesis, both cell therapy companies, and earlier in his career was with Merck Vaccines and McKinsey & Co.
“Steve has tremendous deal experience, as is clear from his track record, which will be valuable in realizing the potential of both our ganetespib and HDC programs,” said Safi Bahcall, president and chief executive officer, Synta. “His wealth of diverse business experiences and insights make him an excellent addition to our executive team, as we manage a growing pipeline and an increasing number of important strategic and operational choices.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important